Braidwell LP Boosts Position in Climb Bio, Inc. $CLYM

Braidwell LP lifted its stake in shares of Climb Bio, Inc. (NASDAQ:CLYM) by 102.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,099,027 shares of the company’s stock after buying an additional 1,569,352 shares during the quarter. Climb Bio comprises about 1.5% of Braidwell LP’s holdings, making the stock its 26th biggest holding. Braidwell LP owned 0.05% of Climb Bio worth $40,411,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Legal & General Group Plc purchased a new position in shares of Climb Bio during the second quarter worth approximately $45,000. XTX Topco Ltd raised its stake in shares of Climb Bio by 19.4% during the fourth quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock worth $139,000 after purchasing an additional 5,668 shares during the last quarter. Virtu Financial LLC purchased a new position in Climb Bio in the 4th quarter valued at $43,000. Blair William & Co. IL purchased a new stake in shares of Climb Bio in the fourth quarter valued at about $44,000. Finally, Hsbc Holdings PLC increased its stake in shares of Climb Bio by 107.2% during the fourth quarter. Hsbc Holdings PLC now owns 24,744 shares of the company’s stock worth $99,000 after acquiring an additional 12,800 shares during the period. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Climb Bio Trading Up 1.6%

CLYM stock opened at $15.05 on Thursday. The company has a market cap of $864.47 million, a PE ratio of -18.13 and a beta of 0.09. The stock has a 50-day moving average price of $13.95 and a two-hundred day moving average price of $10.69. Climb Bio, Inc. has a 12-month low of $1.54 and a 12-month high of $18.33.

Climb Bio (NASDAQ:CLYM) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03. Equities analysts forecast that Climb Bio, Inc. will post -0.82 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. BTIG Research raised their price objective on shares of Climb Bio from $19.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, June 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a report on Friday, July 17th. Wall Street Zen upgraded shares of Climb Bio from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Guggenheim initiated coverage on Climb Bio in a report on Monday, June 8th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Royal Bank Of Canada assumed coverage on shares of Climb Bio in a report on Monday, August 3rd. They set an “outperform” rating and a $23.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $23.08.

Climb Bio Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.